The biochemical and molecular mechanisms involved in the role of tumor micro-environment stress in development of drug resistance
- PMID: 31202693
- DOI: 10.1016/j.bbagen.2019.06.007
The biochemical and molecular mechanisms involved in the role of tumor micro-environment stress in development of drug resistance
Abstract
Background: Multi-drug resistance (MDR) is a leading cause of morbidity and mortality in cancer and it continues to be a challenge in cancer treatment. Moreover, the tumor micro-environment is essential to the formation of drug resistant cancers. Recent evidence indicates that the tumor micro-environment is a critical regulator of cancer progression, distant metastasis and acquired resistance of tumors to various therapies. Despite significant advances in chemotherapy and radiotherapy, the development of therapeutic resistance leads to reduced drug efficacy.
Scope of review: This review highlights mechanistic aspects of the biochemistry of the tumor micro-enviroment, such as the hypoglycaemia, reactive oxygen species (ROS), hypoxia and their effects in propagating MDR. This is achieved through: (A) increased survival via autophagy and failure of apoptosis; (B) altered metabolic processing; and (C) reduction in drug delivery and uptake or increased drug efflux.
Major conclusions: The development of MDR in cancer has been demonstrated to be majorly influenced by naturally occurring stressors within the tumor micro-environment, as well as chemotherapeutics. Thus, the tumor micro-environment is currently emerging as a major focus of research which needs to be carefully addressed before cancer can be successfully treated.
General significance: Elucidating the biochemical mechanisms which promote MDR is essential in development of effective therapeutics that can overcome these acquired defences in cancer cells.
Keywords: Apoptosis; Autophagy; Hypoxia; Metabolism; Multi-drug resistance; Tumor micro-environment.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
-
Tumour Microenvironment Stress Promotes the Development of Drug Resistance.Antioxidants (Basel). 2021 Nov 11;10(11):1801. doi: 10.3390/antiox10111801. Antioxidants (Basel). 2021. PMID: 34829672 Free PMC article. Review.
-
Nanomaterial-induced autophagy: a new reversal MDR tool in cancer therapy?Mol Pharm. 2014 Aug 4;11(8):2527-38. doi: 10.1021/mp500066v. Epub 2014 Jun 20. Mol Pharm. 2014. PMID: 24921216 Review.
-
The multi-factorial nature of clinical multidrug resistance in cancer.Drug Resist Updat. 2019 Sep;46:100645. doi: 10.1016/j.drup.2019.100645. Epub 2019 Sep 17. Drug Resist Updat. 2019. PMID: 31585396 Review.
-
The role of tumor microenvironment in therapeutic resistance.Oncotarget. 2017 Jan 17;8(3):3933-3945. doi: 10.18632/oncotarget.13907. Oncotarget. 2017. PMID: 27965469 Free PMC article. Review.
-
The Role of Intracellular and Extracellular Vesicles in the Development of Therapy Resistance in Cancer.Curr Pharm Des. 2024;30(35):2765-2784. doi: 10.2174/0113816128326325240723051625. Curr Pharm Des. 2024. PMID: 39113303 Review.
Cited by
-
Glycemic load impacts the response of acquired resistance in breast cancer cells to chemotherapeutic drugs in vitro.PLoS One. 2024 Nov 22;19(11):e0311345. doi: 10.1371/journal.pone.0311345. eCollection 2024. PLoS One. 2024. PMID: 39576770 Free PMC article.
-
ERMP1 Facilitates The Malignant Characteristics of Colorectal Cancer Cells through Modulating PI3K/AKT/β-Catenin Pathway and Localization of GRP78.Cell J. 2023 Jul 25;25(7):470-482. doi: 10.22074/cellj.2023.1982707.1188. Cell J. 2023. PMID: 37543860 Free PMC article.
-
Overcoming Chemoresistance: Altering pH of Cellular Compartments by Chloroquine and Hydroxychloroquine.Front Cell Dev Biol. 2021 Feb 9;9:627639. doi: 10.3389/fcell.2021.627639. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33634129 Free PMC article. Review.
-
3D cancer models: One step closer to in vitro human studies.Front Immunol. 2023 Apr 11;14:1175503. doi: 10.3389/fimmu.2023.1175503. eCollection 2023. Front Immunol. 2023. PMID: 37114038 Free PMC article. Review.
-
Metformin and Thymoquinone Synergistically Inhibit Proliferation of Imatinib-Resistant Human Leukemic Cells.Front Pharmacol. 2022 Apr 13;13:867133. doi: 10.3389/fphar.2022.867133. eCollection 2022. Front Pharmacol. 2022. PMID: 35496297 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials